Evaluation and management of cardiac safety using the electrocardiogram in oncology clinical trials: focus on cardiac repolarization (QTc interval).

Morganroth, J; Shah, R R; Scott, J W

Morganroth, J; Shah, R R; Scott, J W.

Affiliation

Morganroth J; eResearchTechnology, Philadelphia, Pennsylvania, USA. Jmorganroth@ert.com

Clin Pharmacol Ther ; 87(2): 166-74, 2010 Feb.

Article in En | MEDLINE | ID: mdl-20010556

Subject(s)

Antineoplastic Agents/adverse effects; Drug Monitoring/methods; Electrocardiography; Long QT Syndrome/chemically induced; Antineoplastic Agents/administration & dosage; Antineoplastic Agents/therapeutic use; Clinical Trials as Topic/methods; Dose-Response Relationship, Drug; Drug Design; Humans; Neoplasms/drug therapy; Patient Selection; Risk Factors

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Long QT Syndrome / Drug Monitoring / Electrocardiography / Antineoplastic Agents Type of study: Etiology_studies / Guideline / Prognostic_studies Limits: Humans Language: En Year: 2010 Type: Article

Fulltext

XML

PubMed Links

Search on Google